Novo Nordisk Pays $58.65M To Settle Claim It Downplayed Victoza Cancer Risk

(September 6, 2017, 11:37 AM EDT) -- WASHINGTON, D.C. — Drug maker Novo Nordisk Inc. on Sept. 5 agreed to pay $58.65 million to settle federal allegations that it instructed sales representatives to downplay a federally required warning...
To view the full article, register now.